Pharmidex
Mo Alavijeh possesses extensive experience in the pharmaceutical and academic sectors, currently serving as Managing Director, Chief Operating Officer, and Chief Scientific Officer at Pharmidex since May 2002. In addition to corporate roles, Alavijeh holds the position of Honorary Professor at the University of Hertfordshire since December 2018. Previous leadership experience includes serving as Department Head at Vernalis from 2000 to 2002 and Team Leader at Sanofi from 1992 to 2000. Academic qualifications include a PhD in Neuropharmacology from University College London and additional training in International Business Growth from the University of Cambridge, among other educational achievements. Alavijeh is also a member of the Marie Curie Alumni Association since 2009.
This person is not in any teams
This person is not in any offices
Pharmidex
Pharmidex is an AAALAC-accredited, UK-based CRO founded in 2002. We provide high-quality, cost-effective, flexible and rapid solutions in drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP/GLP/GCP), toxicology (non-GLP/GLP), histology, clinical chemistry, hematology, and in vitro ADME. Pharmidex also offers in silico modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune, and metabolic disease programs. We work with over 250 global clients, including medical charities, academic groups, biotech, and pharma, and have undertaken over 15,000 studies. In addition to our fee-for-service offering, Pharmidex actively seeks collaboration opportunities in grant-funded projects. To date, we have successfully participated in over 30 collaborative grant-funded projects, partnering with more than 167 global collaborators.